Literature DB >> 7196237

The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man.

W Block, A Pingoud, M Khan, P Kjellerup.   

Abstract

The pharmacokinetics of 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide (metoclopramide, Paspertin) after a single dose of the drug in five different dosage forms: ampoules, tablets, drops, dragées and suppositories, were studied. The clinical investigations were carried out on 10 healthy subjects under carefully controlled conditions. The analysis of metoclopramide in plasma was carried out using reverse-phase high-pressure liquid chromatography. Bioavailabilities between 76 and 79% were determined for the oral application forms and 53% for the rectal application form. Significant differences between maximum plasma levels were found for different individuals. The initial distribution of the drug is very rapid, and the elimination half-lives are comparable for all formulations and ranged from 3.9 and 5.3 h. The apparent volume of distribution is 3.1 l/kg body weight and the total body clearance is 38.4 l/h.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7196237

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  10 in total

Review 1.  Pharmacokinetic optimisation of antiemetic therapy.

Authors:  M Campbell; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Bioavailability of intranasal metoclopramide.

Authors:  M J Ward; D C Buss; J Ellershaw; A Nash; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

4.  Oral bioavailability of high-dose metoclopramide.

Authors:  W B Taylor; D N Bateman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Identification of metoclopramide metabolites in the urine of cattle by gas chromatography-mass spectrometry and high-performance liquid chromatography-photodiode array detection.

Authors:  R D Jones; C D Blanton; J M Bowen
Journal:  Vet Res Commun       Date:  1993       Impact factor: 2.459

6.  Continuous infusion of high-dose metoclopramide for the prevention of nausea and vomiting in patients receiving cancer chemotherapy.

Authors:  R A Joss; R L Galeazzi; K W Brunner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 7.  Pharmacokinetics of high-dose metoclopramide in cancer patients.

Authors:  E M McGovern; J Grevel; S M Bryson
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of metoclopramide.

Authors:  D N Bateman
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

Review 9.  Metoclopramide. An updated review of its pharmacological properties and clinical use.

Authors:  R A Harrington; C W Hamilton; R N Brogden; J A Linkewich; J A Romankiewicz; R C Heel
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

10.  High pressure liquid chromatographic analysis of metoclopramide in serum.

Authors:  J L Cohen; G H Hisayasu; S B Strum
Journal:  Pharm Res       Date:  1984-01       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.